Lucas A M Franco1, Carlos H V Moreira1,2, Lewis F Buss1, Lea C Oliveira1, Roberta C R Martins1, Erika R Manuli1, José A L Lindoso2, Michael P Busch3,4, Alexandre C Pereira5,6, Ester C Sabino1. 1. Department of Infectious Disease and Institute of Tropical Medicine (IMT-SP), University of São Paulo, Av. Dr. Enéas Carvalho de Aguiar, 470, São Paulo 05403-000, Brazil. 2. Institute of Infectology Emílio Ribas, São Paulo 01246-900, Brazil. 3. Blood Systems Research Institute, San Francisco, CA 94118, USA. 4. Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA 94143, USA. 5. Department of Genetics, Harvard Medical School, Boston, MA 02115, USA. 6. Laboratory of Genetics and Molecular Cardiology, The Heart Institute, University of São Paulo, São Paulo 05403-000, Brazil.
Abstract
Chagas disease remains a major social and public health problem in Latin America. Benznidazole (BZN) is the main drug with activity against Trypanosoma cruzi. Due to the high number of adverse drug reactions (ADRs), BZN is underprescribed. The goal of this study was to evaluate the genetic and transcriptional basis of BZN adverse reactions. METHODS: A prospective cohort with 102 Chagas disease patients who underwent BZN treatment was established to identify ADRs and understand their genetic basis. The patients were classified into two groups: those with at least one ADR (n = 73), and those without ADRs (n = 29). Genomic analyses were performed comparing single nucleotide polymorphisms between groups. Transcriptome data were obtained comparing groups before and after treatment, and signaling pathways related to the main ADRs were evaluated. RESULTS: A total of 73 subjects (71.5%) experienced ADRs. Dermatological symptoms were most frequent (45.1%). One region of chromosome 16, at the gene LOC102724084 (rs1518601, rs11861761, and rs34091595), was associated with ADRs (p = 5.652 × 10-8). Transcriptomic data revealed three significantly enriched signaling pathways related to BZN ADRs. CONCLUSIONS: These data suggest that part of adverse BZN reactions might be genetically determined and may facilitate patient risk stratification prior to starting BZN treatment.
Chagas disease remains a major social and public health problem in Latin America. Benznidazole (BZN) is the main drug with activity against Trypanosoma cruzi. Due to the high number of adverse drug reactions (ADRs), BZN is underprescribed. The goal of this study was to evaluate the genetic and transcriptional basis of BZN adverse reactions. METHODS: A prospective cohort with 102 Chagas disease patients who underwent BZN treatment was established to identify ADRs and understand their genetic basis. The patients were classified into two groups: those with at least one ADR (n = 73), and those without ADRs (n = 29). Genomic analyses were performed comparing single nucleotide polymorphisms between groups. Transcriptome data were obtained comparing groups before and after treatment, and signaling pathways related to the main ADRs were evaluated. RESULTS: A total of 73 subjects (71.5%) experienced ADRs. Dermatological symptoms were most frequent (45.1%). One region of chromosome 16, at the gene LOC102724084 (rs1518601, rs11861761, and rs34091595), was associated with ADRs (p = 5.652 × 10-8). Transcriptomic data revealed three significantly enriched signaling pathways related to BZN ADRs. CONCLUSIONS: These data suggest that part of adverse BZN reactions might be genetically determined and may facilitate patient risk stratification prior to starting BZN treatment.
Entities:
Keywords:
Chagas disease; adverse drug reactions; benznidazole; pharmacogenomics
Authors: João Carlos Pinto Dias; Alberto Novaes Ramos; Eliane Dias Gontijo; Alejandro Luquetti; Maria Aparecida Shikanai-Yasuda; José Rodrigues Coura; Rosália Morais Torres; José Renan da Cunha Melo; Eros Antonio de Almeida; Wilson de Oliveira; Antônio Carlos Silveira; Joffre Marcondes de Rezende; Fabiane Scalabrini Pinto; Antonio Walter Ferreira; Anis Rassi; Abílio Augusto Fragata; Andréa Silvestre de Sousa; Dalmo Correia; Ana Maria Jansen; Glaucia Manzan Queiroz Andrade; Constança Felícia De Paoli de Carvalho Britto; Ana Yecê das Neves Pinto; Anis Rassi; Dayse Elisabeth Campos; Fernando Abad-Franch; Silvana Eloi Santos; Egler Chiari; Alejandro Marcel Hasslocher-Moreno; Eliane Furtado Moreira; Divina Seila de Oliveira Marques; Eliane Lages Silva; José Antonio Marin-Neto; Lúcia Maria da Cunha Galvão; Sergio Salles Xavier; Sebastião Aldo da Silva Valente; Noêmia Barbosa Carvalho; Alessandra Viana Cardoso; Rafaella Albuquerque E Silva; Veruska Maia da Costa; Simone Monzani Vivaldini; Suelene Mamede Oliveira; Vera da Costa Valente; Mayara Maia Lima; Renato Vieira Alves Journal: Epidemiol Serv Saude Date: 2016-06
Authors: Israel Molina; Jordi Gómez i Prat; Fernando Salvador; Begoña Treviño; Elena Sulleiro; Núria Serre; Diana Pou; Sílvia Roure; Juan Cabezos; Lluís Valerio; Albert Blanco-Grau; Adrián Sánchez-Montalvá; Xavier Vidal; Albert Pahissa Journal: N Engl J Med Date: 2014-05-15 Impact factor: 91.245
Authors: Melisa D Castro Eiro; María A Natale; Carlos A Vigliano; Susana A Laucella; María G Alvarez; Araceli Castro; Débora Seigelshifer; Rodolfo Viotti; Marisa Fernández; Luis Mazzuoccolo; Bruno Lococo; Graciela L Bertocchi; Gonzalo Cesar; María C Albareda; María J Elias; María B Caputo; Eduardo Gaddi; Jeanette Balbaryski Journal: Microbiol Spectr Date: 2022-08-08